EAN 2026 | One big question with Celia Oreja-Guevara: what MS advance could transform care in the next 3 years?
Celia Oreja-Guevara, MD, PhD, University Hospital San Carlos, Madrid, Spain, discusses the key advances in multiple sclerosis (MS) that could transform care in the next three years. Dr Oreja-Guevara mentions treatments to slow or prevent disease progression, including BTK inhibitors and anti-CD40 antibodies. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think that the most important thing in the next years will be all the treatments to stop or to reduce the progression of the disease. They will be the inhibitors of the BTK, they will be the anti-CD20 and probably the key drugs like the masitinib. So that I think the next five years we will have more treatments to reduce or to treat the progression of the disease and I think we will need to wait more perhaps 10 years to have a remyelinating therapy...
I think that the most important thing in the next years will be all the treatments to stop or to reduce the progression of the disease. They will be the inhibitors of the BTK, they will be the anti-CD20 and probably the key drugs like the masitinib. So that I think the next five years we will have more treatments to reduce or to treat the progression of the disease and I think we will need to wait more perhaps 10 years to have a remyelinating therapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
